Douglas L. Leslie, PhD Associate Professor and Director Research Administration 77 President St, MSC 700 Charleston, SC 29425 Phone: (843) 792-9495 Fax:     (843) 792-3327 E-mail: leslied@musc.edu

Education:

• PhD, Economics, Yale University (1998)
• MPhil., Economics, Yale University (1993)
• MA, Economics, Yale University (1992)
• BA, Economics, University of Virginia (1990)

Areas of Teaching:

• Health Economics

Research Interests:

• Healthcare costs associated with psychiatric disorders
• Economic effects of psychiatric disorders

Publications (10 most recent):

• Chwastiak L, Rosenheck RA and Leslie D. “Impact of Medical Co-morbidity on the Quality of Schizophrenia Pharmacotherapy in a National VA Sample.” Medical Care 2006; 44(1):55-61.
• Petrakis IL, Leslie D, Finney JW and Rosenheck R.  “Atypical antipsychotic medication and substance use-related outcomes in the treatment of schizophrenia.”  American Journal on Addictions 2006; 15(1):44-49.
• Rosenheck RA, Leslie D, Keefe R, McEvoy J, Swartz M, Perkins D, Stroup S, Hsiao J, and Lieberman J.  “Barriers to Employment for People with Schizophrenia.”  American Journal of Psychiatry 2006; 163(3):411-417.
• McAvay GJ, Van Ness PH, Bogardus ST, Zhang Y, Leslie DL, Leo-Summers LS and Inouye SK.  “Older Adults Discharged from the Hospital with Delirium: 1-Year Outcomes.”  Journal of the American Geriatrics Society 2006; 54:1245-1250.
• Gore M, Dukes E, Rowbotham D, Tai KS and Leslie DL.  “Clinical characteristics and pain management among patients with painful peripheral neuropathic disorders in general practice settings.”  European Journal of Pain 2006; Epub ahead of print.
• Gore M, Dukes E, Rowbotham D, Tai KS and Leslie DL.  “Prevalence of contraindicated medical conditions and use of precluded medications in patients with painful neuropathic disorders prescribed amitriptyline.”  Pain Practice 2006; 6(4):265-72.
• Rosenheck RA, Leslie DL, Sindelar J, Miller EA, Lin H, Stroup TS, McEvoy J, Davis S, Keefe RSE, Swartz M, Perkins D, Hsiao JK, Lieberman J for the CATIE Study Investigators. “Cost-Effectiveness of Second Generation Antipsychotics and Perphenazine in a Randomized Trial of Treatment for Chronic Schizophrenia.” American Journal of Psychiatry 2006; 163(12): 2080-2089.
• Leslie DL and Martin A. “Health Care Costs Associated with Autism-Spectrum Disorders.” Archives of Pediatrics and Adolescent Medicine 2007; 161(4):350-355.
• McAvay GJ, Van Ness PH, Bogardus ST, Zhang Y, Leslie DL, Leo-Summers LS and Inouye SK.  “Depressive Symptoms and the Risk of Incident Delirium in Older Hospitalized Adults.”  Journal of the American Geriatrics Society 2007; 55(5): 684-91.
• Rosenheck RA, Leslie DL, Busch S, Rofman ES and Sernyak M. “Rethinking Antipsychotic Formulary Policy.” Schizophrenia Bulletin 2007; Epub ahead of print.

Grants:

• NIMH R01-MH073884; “Patterns of Service Use and Costs Associated with Autism”; PI: Douglas Leslie; 25% effort; Total cost: $586,800; Total cost per year: $195,600; Direct cost per year: $150,000; Grant period: 8/1/06 – 5/31/09.